Quick Answer
Ocugen, Inc. reported R&D Expense of $39.75 million for fiscal year 2025.
Ocugen, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $39.75M | +23.7% |
| 2024 | $32.13M | -18.8% |
| 2023 | $39.57M | +389.4% |
| 2019 | $8.09M | -21.7% |
| 2018 | $10.32M | -33.7% |
| 2017 | $15.57M | -27.9% |
| 2016 | $21.58M | -7.2% |
| 2015 | $23.24M | -10.7% |
| 2014 | $26.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.15M | +37.5% | +32.7% |
| June 30, 2025 | $8.40M | -5.6% | -11.8% |
| March 31, 2025 | $9.53M | +39.6% | +17.5% |
| September 30, 2024 | $8.11M | — | -8.9% |
| June 30, 2024 | $8.90M | — | +30.4% |
| March 31, 2024 | $6.83M | — | +313.1% |
| March 31, 2020 | $1.65M | -56.4% | +26.6% |
| September 30, 2019 | $1.31M | -16.4% | +192.7% |
- Ocugen, Inc. showed an increase of +23.7% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Ocugen, Inc.’s r&d expense has grown by 52.7% (from $26.04 million to $39.75 million).
- The most recent figure is from Ocugen, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: